Evidence map›Paper›PMID 37889115›Full record

ArticleThe Journal of physiology2024

Neutral sphingomyelinase regulates mechanotransduction in human engineered cardiac tissues and mouse hearts.

Daniel G P Turner, Willem J De Lange, Yanlong Zhu, Christopher L Coe, Judith Simcox, Ying Ge, Timothy J Kamp, J Carter Ralphe, Alexey V Glukhov

Open access · hybridAbstract read
In one paragraph

Article in The Journal of physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Caveolae mechanics in cellular functions and disease.Nature reviews. Molecular cell biology · 2026
    Review
  3. Article
  4. Downregulation of L-type CaHeart rhythm · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Daniel G P TurnerDepartment of Medicine, Cardiovascular Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Willem J De LangeDepartment of Pediatrics, Pediatric Cardiology, University of Wisconsin-Madison, Madison, WI, USA.
Yanlong ZhuHuman Proteomics Program, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Christopher L CoeDepartment of Psychology, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-9335-9060
Judith SimcoxDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA.
Ying GeHuman Proteomics Program, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Timothy J KampDepartment of Medicine, Cardiovascular Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0003-2103-7876
J Carter RalpheDepartment of Pediatrics, Pediatric Cardiology, University of Wisconsin-Madison, Madison, WI, USA.
Alexey V GlukhovDepartment of Medicine, Cardiovascular Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0003-2076-9688
University of Wisconsin–Madison · USUniversity of Wisconsin System · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
U19 MIDlife in the United States-Diversity Supplement-WellsU19AG051426 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAROL D. RYFF · 2016 to 2026
$74.8M
STATISTICS COREP01AG020166 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI RYFF, CAROL D. · 2002 to 2015
$50.6M
Integrative Pathways to Cognitive, Affective, and Brain HealthU01AG077928 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson, MARGIE E LACHMAN · 2022 to 2026
$17.7M
Training Program In Molecular AND Cellular PharmacologyT32GM008688 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI AUDHYA, ANJON · 1998 to 2020
$6.0M
Functional Microdomains in the Heart's Pacemaker: A New Dimension of Cardiac RemodelingR01HL141214 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Alexey V Glukhov · 2018 to 2026
$3.8M
Top Down Proteomics Of Myofilaments In Heart FailureR01HL096971 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2011 to 2021
$3.3M
Enabling Top-Down Proteomics through Materials Chemistry and NanotechnologyR01GM117058 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING, JIN, SONG · 2015 to 2023
$2.7M
Ultra High Resolution Mass Spectrometer for Biomedical ResearchS10OD018475 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2015 to 2015
$2.0M
KCNJ2-Induced Arrhythmia Mechanisms in CPVT and Heart Failure.R01HL139738 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI ECKHARDT, LEE LOCHBAUM · 2018 to 2021
$1.5M
Engineered Anisotropic and Vascularized Human Cardiac PatchR01HL146652 · NHLBI · TEXAS ENGINEERING EXPERIMENT STATION · PI ZHAO, FENG · 2020 to 2023
$1.4M
MASH Explorer, a Comprehensive Software Environment for Top-Down ProteomicsR01GM125085 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2018 to 2021
$1.2M
NCI NIH HHS P30 CA014520NHLBI NIH HHS R01 HL096971NHLBI NIH HHS R01 HL139738NHLBI NIH HHS R01 HL141214NHLBI NIH HHS R01 HL146652NIA NIH HHS P01 AG020166NIA NIH HHS R21 AG030166NIA NIH HHS U01 AG077928NIA NIH HHS U19 AG051426NIGMS NIH HHS R01 GM117058NIGMS NIH HHS R01 GM125085NIGMS NIH HHS T32 GM008688NIH HHS S10 OD018475NIH HHS S10 OD023526
6 · The paper itself

Abstract

Cardiovascular disease is the leading cause of death in the USA and is known to be exacerbated by elevated mechanical stress from hypertension. Caveolae are plasma membrane structures that buffer mechanical stress but have been found to be reduced in pathological conditions associated with chronically stretched myocardium. To explore the physiological implications of the loss of caveolae, we used human engineered cardiac tissue (ECT) constructs, composed of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and hiPSC-derived cardiac fibroblasts, to develop a long-term cyclic stretch protocol that recapitulates the effects of hypertension on caveolae expression, membrane tension, and the β-adrenergic response. Leveraging this new stretch protocol, we identified neutral sphingomyelinases (nSMase) as mechanoregulated mediators of caveolae loss, ceramide production and the blunted β-adrenergic response in this human cardiac model. Specifically, in our ECT model, nSMase inhibition via GW4869 prevented stretch-induced loss of caveolae-like structures, mitigated nSMase-dependent ceramide production, and maintained the ECT contractile kinetic response to isoprenaline. These findings are correlated with a blood lipidomic analysis in middle-aged and older adults, which revealed an increase of the circulating levels of ceramides in adults with hypertension. Furthermore, we found that conduction slowing from increased pressure loading in mouse left ventricle was abolished in the context of nSMase inhibition. Collectively, these findings identify nSMase as a potent drug target for mitigating stretch-induced effects on cardiac function. KEY POINTS: We have developed a new stretch protocol for human engineered cardiac tissue that recapitulates changes in plasma membrane morphology observed in animal models of pressure/volume overload. Stretch of engineered cardiac tissue induces activation of neutral sphingomyelinase (nSMase), generation of ceramide, and disassembly of caveolae. Activation of nSMase blunts cardiac β-adrenergic contractile kinetics and mediates stretch-induced slowing of conduction and upstroke velocity. Circulating ceramides are increased in adults with hypertension, highlighting the clinical relevance of stretch-induced nSMase activity.

Indexed as

CeramidesInduced Pluripotent Stem CellsMechanotransduction, CellularMyocytes, CardiacSphingomyelin PhosphodiesteraseTissue EngineeringAniline CompoundsAnimalsBenzylidene CompoundsCaveolaeHumansIsoproterenolMaleMiceMiddle AgedMyocardiumAniline CompoundsBenzylidene CompoundsCeramidesGW 4869IsoproterenolSphingomyelin Phosphodiesterasecaveolaeceramidehypertensionneutral sphingomyelinasestretchtissue engineering

Identifiers

PMID37889115
PMCPMC11052922
OpenAlexW4387965641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.